Formulation: A solid
Formal Name: 4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1H-1,2,4-triazol-3-yl]amino]-N-[2-[[1-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethoxy]ethoxy]ethyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]-benzenesulfonamide
Purity: ≥98%
Formula Markup: C38H42N12O10S2
Formula Weight: 890,9
Shelf life (days): 1460
CAS Number: 2756741-90-7
Notes: CPS2 is a proteolysis-targeting chimera (PROTAC) composed of the Cdk2 binder J2, a derivative of the Cdk and Aurora kinase inhibitor JNJ-7706621 (Item No. 18494), connected to the cereblon inhibitor pomalidomide (Item No. 19877) by a linker region.{51687} It selectively degrades Cdk2 (IC50 = 24 nM) over seven additional CDKs at 500 nM but also degrades Aurora A kinase and Ikaros family zinc finger protein 1 (IKZF1) at 250 nM. CPS2 reduces Cdk2 levels and increases the percentage of cells expressing CD11b, a marker of differentiation, in primary acute myeloid lymphoma (AML) cells. It also decreases proliferation without reducing the viability of, as well as induces differentiation in, primary hematopoietic stem cells (HSCs).